Home > Riviste > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Fascicoli precedenti > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2007 December;51(4) > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2007 December;51(4):314-23

ULTIMO FASCICOLO
 

ARTICLE TOOLS

Estratti

THE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Rivista di Medicina Nucleare e Imaging Molecolare


A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the Society of Radiopharmaceutical Sciences and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,413


eTOC

 

ORIGINAL ARTICLES  ADVANCES IN RADIOIMMUNOIMAGING AND RADIOIMMUNOTHERAPY


The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2007 December;51(4):314-23

lingua: Inglese

Evaluation of [111/114mIn]CHX-A’’-DTPA-ZHER2:342, an Affibody ligand coniugate for targeting of HER2-expressing malignant tumors

Orlova A. 1, 2, Rosik D. 1, Sandström M. 3, Lundqvist H. 2, Einarsson L. 4, Tolmachev V. 1, 2

1 Affibody AB, Bromma, Sweden
2 Division of Biomedical Radiation Sciences Uppsala University, Uppsala, Sweden
3 Department of Hospital Physics Uppsala University Hospital, Uppsala, Sweden
4 The Svedberg Laboratory Uppsala University, Uppsala, Sweden


PDF  


Aim. Radionuclide imaging of the HER2 receptor, which is a target for trastuzumab therapy, can provide important diagnostic information. Further, targeting radionuclide therapy might be an option for treatment of HER2 expressing tumors. The phage-display selected Affibody ligand ZHER2:342, which binds to HER2 with an affinity of 22 pM, may here play an important role. The small size of the ZHER2:342, 7.5 kDa, enables quick tumor localization and fast blood clearance. Earlier, successful targeting of HER2-expressing xenografts using ZHER2:342 labeled using [111In]benzyl-DTPA was reported. By changing to the CHX-A”-DTPA chelator, the stability and labeling kinetics of the radiometal-ZHER2:342 conjugate can be improved. The aim of this study was to evaluate the labeling of the CHX-A”-DTPA-ZHER2:342 conjugate with 111In for diagnostic imaging and with 114mIn for locoregional radionuclide therapy.
Methods. The isothiocyanate derivative of CHX-A”-DTPA was coupled to ZHER2:342 in alkaline conditions at 37 °C. The conjugate was labeled with both 111In and 114mIn and evaluated in vitro and in vivo.
Results. Labeling with 111In and 114mIn provided >95% yield after 30 min at RT. Specific radioactivity was 0.5 and 12 MBq/nmol, for 114mIn and 111In, respectively. The radiolabeled conjugates demonstrated specific binding to HER2 expressing SKOV-3 cells. In mice bearing SKOV-3 xenografts, the tumor uptake of [111In]CHX-A”-DTPA-ZHER2:342 4 h postinjection was 10.3±3.6% IA/g and tumor-to-blood ratio about 190.
Conclusion. [111In]CHX-A”-DTPA-ZHER2:342 is a promising candidate for the visualization of HER2 expression in malignant tumors. Labeled with114mIn it could also be used for locoregional treatment of HER2 expressing tumors.

inizio pagina

Publication History

Per citare questo articolo

Corresponding author e-mail